Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) In Adults with Haematologic Malignancy (HM).

Trial Profile

Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) In Adults with Haematologic Malignancy (HM).

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2011

At a glance

  • Drugs V 212 (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 17 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top